Patient Resources

How the PENTASA Patient Assistance Program May Help Your Patients

Taking PENTASA, each day as prescribed, is an important part of your patients' overall treatment plan. Financial reasons should not prevent your patients from benefiting from PENTASA.

That's why Shire US Inc. sponsors the PENTASA Patient Assistance Program. This program may provide a patient of yours with financial assistance for PENTASA if he or she:

To begin the process of enrolling a patient of yours, download the PENTASA Patient Assistance Program Brochure and Application

Benefits of the PENTASA Patient Assistance Program

Once your patient is enrolled in the program, he or she will receive more helpful information from a PENTASA Patient Assistance Program representative. Specifically, a representative can assist your patient by:

  • Contacting insurers to determine benefits
  • Assisting with the application process

So don't let financial concerns prevent your patients from taking control with PENTASA 500-mg capsules.

To determine if a patient of yours is eligible for the PENTASA Patient Assistance Program or if your patients need help in determining their health care coverage benefits, call 1-866-325-8224.

In order to view PDF documents, you must have Adobe® Reader® installed on your computer.
Get Adobe Reader
If you do not have Adobe Reader, you can download it for free now.

Important Safety Information

  • PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.
  • PENTASA is generally well tolerated. In worldwide clinical trials (N>2100), the most common adverse events were diarrhea (3.4%), headache (2.0%), nausea (1.8%), abdominal pain (1.7%), dyspepsia (1.6%), vomiting (1.5%), and rash (1.0%). As with other mesalamine products, serious adverse events may occur. PENTASA is contraindicated in patients with a hypersensitivity to salicylates. Caution should be used in patients with impaired hepatic or renal function. Patients with pre-existing renal disease, increased BUN or serum creatinine, or proteinuria should be monitored during PENTASA therapy.